T2 Biosystems said it’s launched a clinical trial of its MR-based test for a fungus that’s a common cause of deadly hospital-acquired infections.
The Lexington, Mass.-based company said it plans to use the study results to back a regulatory submission for the T2Candida test for the Candida fungus, estimated to cause some 100,000 cases of candidemia each year in the U.S.